0.6384
Seres Therapeutics Inc stock is traded at $0.6384, with a volume of 1.67M.
It is down -7.91% in the last 24 hours and down -23.99% over the past month.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
See More
Previous Close:
$0.6932
Open:
$0.68
24h Volume:
1.67M
Relative Volume:
1.01
Market Cap:
$109.00M
Revenue:
$126.33M
Net Income/Loss:
$-82.68M
P/E Ratio:
-1.064
EPS:
-0.6
Net Cash Flow:
$-79.98M
1W Performance:
-13.14%
1M Performance:
-23.99%
6M Performance:
-36.11%
1Y Performance:
-17.77%
Seres Therapeutics Inc Stock (MCRB) Company Profile
Name
Seres Therapeutics Inc
Sector
Industry
Phone
617 945 9626
Address
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MCRB
Seres Therapeutics Inc
|
0.6384 | 109.00M | 126.33M | -82.68M | -79.98M | -0.60 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-24-24 | Downgrade | JP Morgan | Neutral → Underweight |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Apr-21-23 | Initiated | JP Morgan | Neutral |
Jul-23-21 | Downgrade | Goldman | Neutral → Sell |
May-18-21 | Resumed | Goldman | Neutral |
Mar-05-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
Sep-18-20 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Aug-18-20 | Initiated | Piper Sandler | Overweight |
Aug-11-20 | Reiterated | H.C. Wainwright | Buy |
Aug-11-20 | Upgrade | Jefferies | Hold → Buy |
Apr-30-19 | Initiated | Jefferies | Hold |
Oct-22-18 | Initiated | Chardan Capital Markets | Buy |
Oct-13-17 | Initiated | Oppenheimer | Outperform |
Aug-04-17 | Reiterated | H.C. Wainwright | Buy |
Feb-01-17 | Reiterated | FBR & Co. | Outperform |
Aug-12-16 | Reiterated | FBR Capital | Outperform |
Aug-01-16 | Downgrade | BofA/Merrill | Buy → Neutral |
Aug-01-16 | Reiterated | H.C. Wainwright | Buy |
Jul-29-16 | Resumed | H.C. Wainwright | Buy |
Mar-30-16 | Initiated | FBR Capital | Outperform |
Mar-03-16 | Initiated | Guggenheim | Buy |
Jan-25-16 | Initiated | H.C. Wainwright | Buy |
Oct-22-15 | Upgrade | BofA/Merrill | Neutral → Buy |
Jul-22-15 | Initiated | Canaccord Genuity | Buy |
Jul-21-15 | Initiated | Goldman | Neutral |
Jul-21-15 | Initiated | Leerink Partners | Outperform |
View All
Seres Therapeutics Inc Stock (MCRB) Latest News
Seres Therapeutics Advances SER-155 Program with FDA Support - TipRanks
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ... - Yahoo Canada Finance
Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and Strategic Developments - GuruFocus.com
Seres Therapeutics Earnings Call: Progress Amid Uncertainty - TipRanks
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Evaluating MCRB’s financial ratios for a profitable investment - US Post News
Seres Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings call transcript: Seres Therapeutics Q4 2024 financial results disappoint - Investing.com India
Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - The Manila Times
Seres Therapeutics Receives FDA Feedback Supporting SER-155 Study Plans for Bloodstream Infection Reduction in Allogeneic Hematopoietic Stem Cell Transplant Patients - Nasdaq
Seres Therapeutics Breakthrough Drug Cuts Infection Risk by 77% in Stem Cell Transplants - StockTitan
Seres Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
StockNews.com Upgrades Seres Therapeutics (NASDAQ:MCRB) to “Hold” - Defense World
Seres Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ: MCRB) Stock Gains Momentum Ahead of Q4 Earnings - DRP Journal
Seres Therapeutics (MCRB) Expected to Announce Earnings on Thursday - Defense World
Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire Inc.
Seres Therapeutics to Announce Fourth Quarter and Full Year - GlobeNewswire
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025 - The Manila Times
FDA supports Seres Therapeutics’ study endpoint - Investing.com India
Seres Therapeutics receives feedback from FDA on SER-155 development approach - TipRanks
Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach - The Manila Times
FDA supports Seres Therapeutics' study endpoint - Investing.com
FDA supports Seres Therapeutics’ study endpoint By Investing.com - Investing.com Australia
Seres Therapeutics Receives Feedback From FDA on SER-155 - GlobeNewswire
Can Seres' SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint - StockTitan
Seres Therapeutics (MCRB) Expected to Announce Earnings on Tuesday - Defense World
5 Best Microbiome Companies (March 2025) - Securities.io
Seres Therapeutics (MCRB) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Downgraded to "Sell" Rating by StockNews.com - MarketBeat
Seres Therapeutics, Inc.'s (NASDAQ:MCRB) market cap dropped US$15m last week; individual investors who hold 50% were hit as were institutions - Simply Wall St
Seres Therapeutics, Inc. Receives Feedback from Fda on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach - Marketscreener.com
Seres Therapeutics Announces CMO Resignation in March 2025 - TipRanks
Investor Network: Seres Therapeutics Inc to Host Earnings Call - ACCESS Newswire
Seres Therapeutics (NASDAQ:MCRB) Downgraded by StockNews.com to “Sell” - Defense World
Seres Therapeutics, Inc. (NASDAQ:MCRB) Shares Purchased by Vontobel Holding Ltd. - MarketBeat
Seres Therapeutics executive sells shares worth $3,579 By Investing.com - Investing.com Nigeria
Seres Therapeutics officer sells $3,203 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics, Inc. (NASDAQ:MCRB) CEO Eric D. Shaff Sells 12,726 Shares - MarketBeat
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock - Investing.com India
Seres Therapeutics EVP sells $2,704 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics CEO Eric Shaff sells $10,314 in stock By Investing.com - Investing.com South Africa
Seres Therapeutics exec Thomas Desrosier sells $3,485 in stock - Investing.com
Seres Therapeutics executive sells shares worth $3,579 - Investing.com
Seres Therapeutics EVP sells $2,704 in stock - Investing.com
Seres Therapeutics officer sells $3,203 in stock - Investing.com
Seres Therapeutics (NASDAQ:MCRB) Rating Increased to Hold at StockNews.com - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Stock Crosses Below 50-Day Moving AverageWhat's Next? - MarketBeat
Seres Therapeutics (NASDAQ:MCRB) Upgraded at StockNews.com - Defense World
Seres Therapeutics Inc (NASDAQ: MCRB) Stock Jumped 6.76% Over A Month – Is There Any Hope Of A Gain? - Marketing Sentinel
Janney Montgomery Scott LLC Lowers Stock Holdings in Seres Therapeutics, Inc. (NASDAQ:MCRB) - Defense World
Seres Therapeutics Inc Stock (MCRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):